Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFLUCAN IN SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole, a bis-triazole antifungal, selectively inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of candidemia and disseminated candidiasis (including hepatosplenic candidiasis and fungal peritonitis),Treatment of oropharyngeal and esophageal candidiasis,Treatment of vulvovaginal candidiasis (acute and recurrent),Treatment of cryptococcal meningitis,Prophylaxis of candidiasis in bone marrow transplant recipients undergoing chemotherapy or radiation therapy,Off-label: Treatment of coccidioidomycosis, histoplasmosis, blastomycosis, and tinea infections (e.g., tinea pedis, corporis, cruris),Off-label: Prophylaxis of fungal infections in patients with prolonged neutropenia or HIV/AIDS
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
400 mg IV on day 1, then 200 mg IV once daily; for esophageal candidiasis: 200 mg IV on day 1, then 100 mg IV once daily
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is approximately 30 hours (range 20-50 hours) in adults with normal renal function. Prolonged in renal impairment (up to 98 hours in creatinine clearance <20 m L/min).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Primarily hepatic metabolism via cytochrome P450 isoenzymes (CYP2C9, CYP3A4, and to a lesser extent CYP2C19). Fluconazole is a moderate inhibitor of CYP2C9 and CYP3A4 and a weak inhibitor of CYP2C19. Approximately 80% of an administered dose is excreted unchanged in urine; the remainder is excreted as metabolites.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal excretion of unchanged drug (~80% of dose). Approximately 11% excreted as metabolites. Biliary/fecal excretion accounts for <5%.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Plasma protein binding is 11-12%, primarily to albumin. The low binding results in extensive free drug distribution.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Volume of distribution (Vd) is approximately 0.7 L/kg (range 0.5-0.9 L/kg), indicating extensive distribution into total body water and tissues, including penetration into cerebrospinal fluid (CSF), vitreous humor, and peritoneal fluid.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral bioavailability is >90%, essentially complete. Absorption is unaffected by gastric p H or food. Intravenous bioavailability is 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Cr Cl >50 m L/min: no adjustment; Cr Cl 21-50 m L/min: administer 50% of usual dose; Cr Cl 11-20 m L/min: administer 25% of usual dose; intermittent hemodialysis: administer full dose after each dialysis session
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Child-Pugh Class A and B: no adjustment; Child-Pugh Class C: insufficient data, use with caution
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Neonates (0-14 days): 6-12 mg/kg IV every 72 hours; Infants/Children (15 days-1 year): 6-12 mg/kg IV every 24 hours; Children >1 year: 6-12 mg/kg IV every 24 hours; maximum 400 mg/day
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
No specific dose adjustment recommended; monitor renal function and adjust dose based on creatinine clearance due to age-related renal impairment
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None
None.
Hepatotoxicity: Elevations in liver enzymes have been observed; rare cases of severe hepatic necrosis and fatal hepatic failure have occurred. Discontinue if signs of hepatic injury develop.,QT prolongation: Fluconazole may prolong the QT interval, potentially leading to torsade de pointes. Caution in patients with electrolyte disturbances, bradyarrhythmias, or concurrent use of other QT-prolonging drugs.,Adrenal insufficiency: Cases of reversible adrenal insufficiency have been reported, particularly in patients receiving corticosteroids or those with stress.,Dermatologic reactions: Exfoliative skin disorders (e.g., Stevens-Johnson syndrome) may occur. Discontinue if rash progresses.,Renal impairment: Dose adjustment required in patients with renal dysfunction (Cr Cl <50 m L/min) due to extensive renal elimination.,Pregnancy: Use only if benefit outweighs risk; single-dose therapy for vulvovaginal candidiasis is not recommended during pregnancy.,Lactation: Fluconazole is excreted in human milk; caution in nursing mothers.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to fluconazole or any azole antifungal,Concurrent use of terfenadine (when used at multiple doses of fluconazole ≥400 mg/day) due to risk of serious cardiac arrhythmias,Concurrent use of cisapride due to increased risk of QT prolongation and torsade de pointes,Concurrent use of quinidine, pimozide, or ergot alkaloids (e.g., ergotamine) due to potential for serious adverse effects
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions. Avoid alcohol due to potential hepatotoxicity.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Fluconazole is contraindicated in the first trimester except for treatment of serious fungal infections where benefit outweighs risk. First trimester: increased risk of spontaneous abortion and congenital anomalies (e.g., craniosynostosis, cardiac defects, cleft lip/palate) with prolonged high-dose therapy (≥400 mg/day). Second and third trimesters: low risk at single 150 mg dose; high-dose prolonged use may cause fetal toxicity. Category D for first trimester; Category C for later trimesters.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Fluconazole is excreted into human breast milk with an estimated infant dose of 0.9–3.7% of maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.9–1.0. Single 150 mg dose is considered compatible with breastfeeding. Avoid high-dose prolonged therapy during lactation due to potential infant accumulation and adverse effects (e.g., hepatic toxicity).
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No specific dose adjustment is required for single 150 mg dose for vaginal candidiasis. For systemic infections, use standard dosing (200–400 mg/day) but monitor maternal toxicity and fetal effects. Consider alternative therapy in first trimester. Due to increased volume of distribution and renal clearance in pregnancy, higher doses may be required for life-threatening infections; however, benefit-risk must be evaluated.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Do not use with other fluconazole formulations to avoid dose errors. Monitor renal function and adjust dose in creatinine clearance <50 m L/min. Infuse over 1-2 hours; avoid rapid infusion due to risk of QT prolongation. Check for drug interactions with warfarin, sulfonylureas, phenytoin, and CYP2C9 substrates.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is used to treat fungal infections and is given intravenously.,Report any signs of liver problems (dark urine, yellowing eyes/skin, abdominal pain) or irregular heartbeat immediately.,Avoid alcohol consumption during treatment and for several days after completion.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment early even if you feel better; complete the full course.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFLUCAN IN SODIUM CHLORIDE 0.9% vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DIFLUCAN IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Fluconazole, a bis-triazole antifungal, selectively inhibits fungal cytochrome P450 14α-demethylase (CYP51), blocking the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. This disrupts membrane integrity and function, leading to fungal cell death.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFLUCAN IN SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFLUCAN IN SODIUM CHLORIDE 0.9% is: 400 mg IV on day 1, then 200 mg IV once daily; for esophageal candidiasis: 200 mg IV on day 1, then 100 mg IV once daily. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DIFLUCAN IN SODIUM CHLORIDE 0.9% and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DIFLUCAN IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Fluconazole is contraindicated in the first trimester except for treatment of serious fungal infections where benefit outweighs risk. First trimester: increased risk of spontaneous. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.